共 238 条
[1]
Piccart-Gebhart MJ(2005)Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer N Engl J Med 353 1659-1672
[2]
Procter M(2005)Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer N Engl J Med 353 1673-1684
[3]
Leyland-Jones B(2007)Two-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial Lancet 369 29-36
[4]
Goldhirsch A(2011)Treatment with trastuzumab for 1 year after adjuvant chemotherapy in patients with HER2-positive early breast cancer: a 4-year follow-up of a randomised controlled trial Lancet Oncol 12 236-244
[5]
Untch M(2011)Four-year follow-up of trastuzumab plus adjuvant chemotherapy for operable human epidermal growth factor receptor 2-positive breast cancer: joint analysis of data from NCCTG N9831 and NSABP B-31 J Clin Oncol 29 3366-3373
[6]
Smith I(2002)Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer J Clin Oncol 20 719-726
[7]
Romond EH(2006)Outcome of patients with HER2-positive advanced breast cancer progressing during trastuzumab-based therapy Oncologist 11 318-324
[8]
Perez EA(2009)Resistance to trastuzumab in breast cancer Clin Cancer Res 15 7479-7491
[9]
Bryant J(2012)Trastuzumab: updated mechanisms of action and resistance in breast cancer Front Oncol 2 62-240
[10]
Suman VJ(2008)Tyrosine1248-phosphorylated HER2 expression and HER2 gene amplification in female invasive ductal carcinomas Breast Cancer 15 231-645